{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:03:45Z","timestamp":1790899425872,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:00Z","timestamp":1746921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>This review examines the latest progress of \u03b2-lactam antibiotics, focusing on penems. Penems are distinguished by their unique structural characteristics and remarkable antibacterial activity. The structural characteristics of the class that differentiate it from carbapenems or monobactams are addressed. Notable representatives such as sulopenem and faropenem are discussed. Faropenem\u2019s stability and efficacy against resistant bacterial strains emphasize the therapeutic potential of penems. The review highlights sulopenem\u2019s recent FDA approval, marking a key point in treating uncomplicated urinary tract infections caused by specific bacteria in adult women with minimal or no other options for oral antibiotic treatment. The review covers sulopenem\u2019s structural considerations, physicochemical properties, mechanisms of action, antibacterial activity, and clinical pharmacology. The development of penem derivatives is also addressed, emphasizing their potential in combating resistant bacterial infections. Despite having few approved representatives, penems show promising prospects for future design and may significantly contribute to the fight against bacterial resistance. The review also highlights the challenges and future possibilities in penem research, including the need for improved oral bioavailability and the potential for combination therapies with \u03b2-lactamase inhibitors. Overall, penems are valuable antibacterial agents in the antimicrobial arsenal, offering hope in the ongoing battle against multidrug-resistant pathogens.<\/jats:p>","DOI":"10.3390\/molecules30102126","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T06:17:08Z","timestamp":1747030628000},"page":"2126","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Recent Developments in Penem Antibiotics: Structural and Therapeutic Perspectives"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-6903","authenticated-orcid":false,"given":"Aura","family":"Rusu","sequence":"first","affiliation":[{"name":"Pharmaceutical and Therapeutic Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-4063","authenticated-orcid":false,"given":"Octavia-Laura","family":"Oancea","sequence":"additional","affiliation":[{"name":"Organic Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, 540142 Targu Mures, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6862-7449","authenticated-orcid":false,"given":"Elena","family":"Donici","sequence":"additional","affiliation":[{"name":"Scientific Center for Drug Research, Pharmaceutical and Toxicological Chemistry Department, \u201cNicolae Testemitanu\u201d State University of Medicine and Pharmacy, 165 Bd. Stefan Cel Mare si Sfant, MD-2004 Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-2243","authenticated-orcid":false,"given":"Livia","family":"Uncu","sequence":"additional","affiliation":[{"name":"Scientific Center for Drug Research, Pharmaceutical and Toxicological Chemistry Department, \u201cNicolae Testemitanu\u201d State University of Medicine and Pharmacy, 165 Bd. Stefan Cel Mare si Sfant, MD-2004 Chisinau, Moldova"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"112829","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"\u03b2-lactam antibiotics: An overview from a medicinal chemistry perspective","volume":"208","author":"Lima","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.11622\/smedj.2015105","article-title":"Alexander Fleming (1881\u20131955): Discoverer of penicillin","volume":"56","author":"Tan","year":"2015","journal-title":"Singap. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drup.2017.11.002","article-title":"An update on \u03b2-lactamase inhibitor discovery and development","volume":"36","author":"Docquier","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"ref_4","unstructured":"Pandey, N., and Cascella, M. (2025). Beta-Lactam Antibiotics. StatPearls, StatPearls Publishing."},{"key":"ref_5","unstructured":"(2025, January 29). PubChem, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/."},{"key":"ref_6","unstructured":"Aronson, J.K. (2006). Beta-lactam antibiotics. Meyler\u2032s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Elsevier. [15th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/all.13037","article-title":"Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity","volume":"72","author":"Chiriac","year":"2017","journal-title":"Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1021\/ja00515a026","article-title":"The penems, a new class of .beta.-lactam antibiotics. 4. Syntheses of racemic and enantiomeric penem carboxylic acids","volume":"101","author":"Pfaendler","year":"1979","journal-title":"J. Am. Chem. Soc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.bcp.2005.12.003","article-title":"Redefining penems","volume":"71","author":"Dalhoff","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e01898-24","DOI":"10.1128\/spectrum.01898-24","article-title":"Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates","volume":"13","author":"Maher","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molmed.2020.05.001","article-title":"Antibiotic Resistance by Enzymatic Modification of Antibiotic Targets","volume":"26","author":"Schaenzer","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_12","first-page":"292","article-title":"Chapter 19\u2014Antibiotics resistance mechanism","volume":"Volume 1","author":"Hashmi","year":"2020","journal-title":"Antibiotics and Antimicrobial Resistance Genes in the Environment"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"dlac125","DOI":"10.1093\/jacamr\/dlac125","article-title":"A systematic scoping review of faropenem and other oral penems: Treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems","volume":"4","author":"Gandra","year":"2022","journal-title":"JAC-Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1128\/AAC.45.7.1964-1971.2001","article-title":"Pseudomonas aeruginosa Reveals High Intrinsic Resistance to Penem Antibiotics: Penem Resistance Mechanisms and Their Interplay","volume":"45","author":"Okamoto","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Gotte, M., Berghuis, A., Matlashewski, G., Wainberg, M., and Sheppard, D. (2014). The Mechanisms of Resistance to \u03b2-Lactam Antibiotics. Handbook of Antimicrobial Resistance, Springer.","DOI":"10.1007\/978-1-4939-0667-3"},{"key":"ref_16","unstructured":"Center for Drug Evaluation and Research (2024, December 09). FDA Approves New Treatment for Uncomplicated Urinary Tract Infections in Adult Women Who Have Limited or no Alternative Oral Antibiotic Treatment Options, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no."},{"key":"ref_17","unstructured":"Katritzky, A.R., Ramsden, C.A., Scriven, E.F.V., and Taylor, R.J.K. (2008). 2.03\u2014Penicillins. Comprehensive Heterocyclic Chemistry III, Elsevier."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/14787210.5.2.185","article-title":"Faropenem: Review of a new oral penem","volume":"5","author":"Schurek","year":"2007","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-022-01688-1","article-title":"Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria","volume":"82","author":"Zhanel","year":"2022","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1128\/AAC.00296-11","article-title":"Carbapenems: Past, Present, and Future","volume":"55","author":"Endimiani","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1469-0691.2007.01868.x","article-title":"Parenteral carbapenems","volume":"14","author":"Shah","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_22","unstructured":"Center for Drug Evaluation and Research (2019). FDA Drug Safety Communication: FDA Approves Label Changes for Antibacterial Doribax (Doripenem) Describing Increased Risk of Death for Ventilator Patients with Pneumonia."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/jac\/39.1.35","article-title":"The in-vitro activity of faropenem, a novel oral penem","volume":"39","author":"Woodcock","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1248\/yakushi.121.915","article-title":"New orally active penem antibiotic: Farom","volume":"121","author":"Ishiguro","year":"2001","journal-title":"Yakugaku Zasshi"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"(2008). Faropenem Medoxomil: A0026, BAY 56-6854, BAY 566854, Faropenem Daloxate, SUN 208, SUN A0026. Drugs R&D, 9, 115\u2013124.","DOI":"10.2165\/00126839-200809020-00005"},{"key":"ref_26","unstructured":"(2025, January 10). NCATS Inxight Drugs\u2014FAROPENEM. Available online: https:\/\/drugs.ncats.io\/drug\/F52Y83BGH3."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/cid\/ciw055","article-title":"Faropenem Consumption is Increasing in India","volume":"62","author":"Gandra","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Takahashi, M., Hagiya, H., Higashionna, T., Nakano, Y., Sato, K., Haruki, Y., Haruki, M., Honda, H., Ogawa, H., and Ueda, K. (2022). Antimicrobial prescription practices for outpatients with uncomplicated cystitis in Japan. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-09946-8"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/cid\/ciw143","article-title":"The Need for Global Regulation of Antibiotics: The Case of a Generic Oral Penem","volume":"62","author":"Tiberi","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","unstructured":"Hayashi, Y., and Baba, H. (2017). Faropenem. Kucers\u2019 The Use of Antibiotics, CRC Press."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"0223","DOI":"10.1358\/dof.2002.027.03.659134","article-title":"Faropenem daloxate","volume":"27","author":"Sorbera","year":"2002","journal-title":"Drugs Future"},{"key":"ref_32","unstructured":"(2021, January 25). Recommendations of the SEC (Antimicrobial & Antiviral). Proceedings of the 103nd Meeting SEC (Antimicrobial & Antiviral) at CDSCO HQ, New Delhi, India."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000070616","article-title":"The Art of Fusion: From Penams and Cephems to Penems","volume":"49","author":"Dalhoff","year":"2003","journal-title":"Chemotherapy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/jac\/39.3.415","article-title":"Pharmacodynamic properties of faropenem demonstrated by studies of time-kill kinetics and postantibiotic effect","volume":"39","author":"Boswell","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1128\/AAC.00971-07","article-title":"National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study","volume":"51","author":"Critchley","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1345\/aph.1G232","article-title":"Faropenem medoxomil","volume":"42","author":"Gettig","year":"2008","journal-title":"Ann. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s13312-022-2648-5","article-title":"Oral Faropenem Sodium\u2014Implications for Antimicrobial Resistance and Treatment Effectiveness","volume":"59","author":"Dharmapalan","year":"2022","journal-title":"Indian Pediatr."},{"key":"ref_38","unstructured":"Iterum Therapeutics (2025, January 09). Our Promise. Available online: https:\/\/www.iterumtx.com\/our-science\/our-promise."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijantimicag.2018.10.011","article-title":"Infections by multidrug-resistant Gram-negative Bacteria: What\u2032s new in our arsenal and what\u2032s in the pipeline?","volume":"53","author":"Koulenti","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_40","unstructured":"FDA ORLYNVAH (2025, January 30). Full Prescribing Information. Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213972s000lbl.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7164\/antibiotics.43.422","article-title":"Pharmacokinetic studies in animals of a new parenteral penem CP-65,207 and its oral prodrug ester","volume":"43","author":"Gootz","year":"1990","journal-title":"J. Antibiot."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative Review of the Carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11908-024-00831-1","article-title":"Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?","volume":"26","author":"Mangum","year":"2024","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/AAC.01557-08","article-title":"Antianaerobic Activity of Sulopenem Compared to Six Other Agents","volume":"53","author":"Ednie","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.1944.02850510015003","article-title":"The effect of para-aminohippuric acid on plasma concentration of penicillin in man","volume":"126","author":"Beyer","year":"1944","journal-title":"J. Am. Med. Assoc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12012-011-9145-8","article-title":"The History and Future of Probenecid","volume":"12","author":"Robbins","year":"2012","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_47","unstructured":"Merck KGaA (2025, February 14). Sulopenem = 98 HPLC 120788-07-0. Available online: https:\/\/www.sigmaaldrich.com\/RO\/en\/product\/sigma\/pz0042?srsltid=AfmBOooaWuO-xeOH6DyaEUqKUdtv2GDyXQkL58g5KIgUIjcCcVUpXF_v."},{"key":"ref_48","unstructured":"(2025, February 28). Marvin\u2014Chemical Drawing Software. Available online: https:\/\/chemaxon.com\/marvin."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: The DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_50","unstructured":"Chemical Book (2025, February 11). Sulopenem | 120788-07-0. Available online: https:\/\/www.chemicalbook.com\/ChemicalProductProperty_EN_CB81116702.htm."},{"key":"ref_51","unstructured":"(2025, February 14). Tocris Certificate of Analysis\u2014Sulopenem. Available online: https:\/\/resources.rndsystems.com\/pdfs\/tocris_coa\/6337_1_coa.pdf?t=1739444997."},{"key":"ref_52","unstructured":"DRUGBANK Online (2025, April 04). Sulopenem. Available online: https:\/\/go.drugbank.com\/drugs\/DB15284."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_54","unstructured":"DRUGBANK Online (2025, January 09). Sulopenem Etzadroxil. Available online: https:\/\/www.semanticscholar.org\/topic\/sulopenem\/1469849."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"iv23","DOI":"10.1093\/jac\/dkab352","article-title":"Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections","volume":"76","author":"Bassetti","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","unstructured":"Kim, P. (2025, April 03). Sulopenem Etzadroxil\/Probenecid, Available online: https:\/\/www.fda.gov\/media\/181598\/download."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1093\/ofid\/ofx163.1369","article-title":"A Phase 1 Study to Assess the Pharmacokinetics of Sulopenem Etzadroxil (PF-03709270)","volume":"4","author":"Dunne","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial","volume":"76","author":"Dunne","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial","volume":"76","author":"Dunne","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cmi.2024.10.025","article-title":"A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections","volume":"31","author":"Dunne","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.1093\/ofid\/ofaa515.1898","article-title":"LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil\/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial","volume":"7","author":"Dunne","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1093\/ofid\/ofaa439.1417","article-title":"1232. Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil\/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial","volume":"7","author":"Dunne","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_63","unstructured":"Iterum Therapeutics PLC (2025, February 17). Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAHTM (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections. Available online: https:\/\/ir.iterumtx.com\/press-releases\/detail\/136\/iterum-therapeutics-receives-u-s-fda-approval-of."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"ofad500.2185","DOI":"10.1093\/ofid\/ofad500.2185","article-title":"2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model","volume":"10","author":"VanScoy","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_65","unstructured":"(2025, April 04). Pfizer A Phase 2 Randomized, Double-Blind, Double-Dummy Efficacy, Safety And Tolerability Study Of Iv Sulopenem With Switch To Oral Pf-03709270 Compared To Ceftriaxone With Step Down To Amoxicillin&#x2F;Clavulanate Potassium (Augmentin) In Subjects With Community Acquired Pneumonia (Cap) Requiring Hospitalization. Available online: https:\/\/clinicaltrials.gov\/study\/NCT00797108."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jac\/39.5.575","article-title":"In-vitro microbiological assessment of a new penem, Men 10700","volume":"39","author":"Shah","year":"1997","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.7164\/antibiotics.53.1086","article-title":"Synthesis and biological activity of the penem antibiotic MEN 10700 and its orally absorbed ester MEN 11505","volume":"53","author":"Arcamone","year":"2000","journal-title":"J. Antibiot."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000048582","article-title":"MEN 10700, a new penem antibiotic: In vitro antibacterial activity on clinical isolates","volume":"48","author":"Ferrari","year":"2002","journal-title":"Chemotherapy"},{"key":"ref_69","unstructured":"Syst\u00e8mes, D. (2025, February 18). BIOVIA Draw for Academics Thank You. Available online: https:\/\/discover.3ds.com\/biovia-draw-academic-thank-you."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/jac\/44.3.381","article-title":"Antipneumococcal activity of MEN 10700, a new penem, compared with other compounds, by MIC and time\u2013kill kinetics","volume":"44","author":"Pankuch","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1016\/j.bmc.2004.08.039","article-title":"Novel imidazole substituted 6-methylidene-penems as broad-spectrum \u03b2-lactamase inhibitors","volume":"12","author":"Venkatesan","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.bmc.2007.11.006","article-title":"5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of \u03b2-lactamases","volume":"16","author":"Venkatesan","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1016\/j.bmcl.2009.04.034","article-title":"Synthesis and biological evaluation of penem inhibitors of bacterial signal peptidase","volume":"19","author":"Harris","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/AAC.01047-08","article-title":"Establishment of In Vitro Susceptibility Testing Methodologies and Comparative Activities of Piperacillin in Combination with the Penem \u03b2-Lactamase Inhibitor BLI-489","volume":"53","author":"Petersen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dkaa421","article-title":"In vitro and in vivo activities of imipenem combined with BLI-489 against class D \u03b2-lactamase-producing Acinetobacter baumannii","volume":"76","author":"Wang","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jac\/dkac037","article-title":"Synergistic effect of the novel \u03b2-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales","volume":"77","author":"Shi","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","unstructured":"(2025, April 01). Wyeth (Registry Contact: Clinical Trial Registry Specialist) Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects. Available online: https:\/\/clinicaltrials.gov\/study\/NCT00820404."},{"key":"ref_78","unstructured":"(2025, April 01). Wyeth (Registry Contact: Clinical Trial Registry Specialist) A Randomized, Open-label, Single-dose, 3-period Crossover Study to Describe the Pharmacokinetic Parameters of BLI-489 and Piperacillin When Administered Simultaneously Compared to When Each is Administered Alone, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00894439."},{"key":"ref_79","unstructured":"(2025, April 01). Wyeth is now a wholly owned subsidiary of Pfizer Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Japanese Male Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00854009."},{"key":"ref_80","unstructured":"(2025, April 01). Wyeth is now a wholly owned subsidiary of Pfizer Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00909688."},{"key":"ref_81","first-page":"156","article-title":"Antimicrobial Activities of Ferrocenyl Complexes: A Review","volume":"8","author":"Hassan","year":"2018","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Costa, N.C.S., Piccoli, J.P., Santos-Filho, N.A., Clementino, L.C., Fusco-Almeida, A.M., Annunzio, S.R.D., Fontana, C.R., Verga, J.B.M., Eto, S.F., and Pizauro-Junior, J.M. (2020). Antimicrobial activity of RP-1 peptide conjugate with ferrocene group. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228740"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"22054","DOI":"10.1039\/D2RA04587G","article-title":"A green synthesis and antibacterial activity of ferrocene-based thiazole derivatives in choline chloride\/glycerol eutectic solvent","volume":"12","author":"Zhao","year":"2022","journal-title":"RSC Adv."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Snegur, L.V. (2022). Modern Trends in Bio-Organometallic Ferrocene Chemistry. Inorganics, 10.","DOI":"10.3390\/inorganics10120226"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.ejmech.2009.12.045","article-title":"Synthesis, characterization and antibacterial activities of some new ferrocene-containing penems","volume":"45","author":"Long","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1021\/acs.biochem.5b00698","article-title":"Kinetic and Structural Characterization of the Interaction of 6-Methylidene Penem 2 with the \u03b2-Lactamase from Mycobacterium tuberculosis","volume":"54","author":"Hazra","year":"2015","journal-title":"Biochemistry"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Batchelder, H.R., Story-Roller, E., Lloyd, E.P., Kaushik, A., Bigelow, K.M., Maggioncalda, E.C., Nuermberger, E.L., Lamichhane, G., and Townsend, C.A. (2020). Development of a penem antibiotic against Mycobacteroides abscessus. Commun. Biol., 3.","DOI":"10.1038\/s42003-020-01475-2"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/acsinfecdis.2c00229","article-title":"Structure\u2013Activity Relationship of Penem Antibiotic Side Chains Used against Mycobacteria Reveals Highly Active Compounds","volume":"8","author":"Batchelder","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e00536-22","DOI":"10.1128\/aac.00536-22","article-title":"T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with \u03b2-Lactams Imipenem and Cefditoren","volume":"66","author":"Rimal","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","unstructured":"WHO (2025, April 03). Lack of Innovation Set to Undermine Antibiotic Performance and Health Gains. Available online: https:\/\/www.who.int\/news\/item\/22-06-2022-22-06-2022-lack-of-innovation-set-to-undermine-antibiotic-performance-and-health-gains."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Br\u00fcssow, H. (2024). The antibiotic resistance crisis and the development of new antibiotics. Microb. Biotechnol., 17.","DOI":"10.1111\/1751-7915.14510"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2126\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:57Z","timestamp":1760031057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/30\/10\/2126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":91,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["molecules30102126"],"URL":"https:\/\/doi.org\/10.3390\/molecules30102126","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]}}}